Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficient disruption of bcr-abl gene by CRISPR RNA-guided FokI nucleases depresses the oncogenesis of chronic myeloid leukemia cells

28 May 2019

Abstract excerpt

BACKGROUND: The bcr-abl fusion gene encodes BCR-ABL oncoprotein and plays a crucial role in the leukemogenesis of chronic myeloid leukemia (CML). Current therapeutic methods have limited treatment effect on CML patients with drug resistance or disease relapse. Therefore, novel therapeutic strategy for CML is essential to be explored and the CRISPR RNA-guided FokI nucleases (RFNs) meet the merits of variable...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to CRISPR and Genetic Engineering

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31138265
DOI: 10.1186/s13046-019-1229-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficient disruption of bcr-abl gene by CRISPR RNA-guided FokI nucleases depresses the oncogenesis of chronic myeloid leukemia cellsPMID 31138265Read ↗

Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleasesSemantic proximity Read ↗

CRISPR/Cas9 technology abolishes the <i>BCR/ABL1</i> oncogene in chronic myeloid leukemia and restores normal hematopoiesisSemantic proximity Read ↗

ABL Genomic Editing Sufficiently Abolishes Oncogenesis of Human Chronic Myeloid Leukemia Cells In Vitro and In VivoSemantic proximity Read ↗

Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a reviewSemantic proximity Read ↗

The high-performance technology CRISPR/Cas9 improves knowledge and management of acute myeloid leukemia.Semantic proximity Read ↗

T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system.Semantic proximity Read ↗

Non-Coding RNAs Are Implicit in Chronic Myeloid Leukemia Therapy ResistanceSemantic proximity Read ↗

The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia.Semantic proximity Read ↗

CRISPR/Cas9-directed Gene Trap Constitutes a Selection System for Corrected BCR/ABL Leukemic Cells in CMLSemantic proximity Read ↗

Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system.Semantic proximity Read ↗

SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells.Semantic proximity Read ↗

CRISPR/Cas9-mediated microRNA-21 Cleavage Sensitizes the Treatment Response to Dasatinib in Chronic Myeloid Leukemia Cell Line K562Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.